tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ohye H et al. Effects of immunosuppressant agents on growth hormone release and gene expression. 1998 Endocr. J. pmid:9790238
Casavilla FA et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. 1998 Liver Transpl Surg pmid:9791154
Toshima K et al. Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes-treated rats. 1998 J. Gastroenterol. Hepatol. pmid:9792034
Sengoku T et al. [Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice]. 1998 Nippon Yakurigaku Zasshi pmid:9793077
Hashimoto Y et al. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. 1998 Pharm. Res. pmid:9794505
Kobayashi M et al. Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. 1998 Nephrol. Dial. Transplant. pmid:9794552
Schaefer A et al. Stimulation of the Ca2+-mediated egr-1 and c-fos expression in murine erythroleukaemia cells by cyclosporin A. 1998 Biochem. J. pmid:9794788
Whitcup SM et al. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. 1998 Ocul. Immunol. Inflamm. pmid:9798194
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Garcia-Criado FJ et al. Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. 1998 Transplantation pmid:9798713
Fisher NC Renal failure after lung transplantation. 1998 Lancet pmid:9800782
Conti F et al. Low level of interleukin 10 synthesis during liver allograft rejection. 1998 Lab. Invest. pmid:9800954
Reis A et al. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. 1998 Graefes Arch. Clin. Exp. Ophthalmol. pmid:9801895
Bieber T Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. 1998 J. Allergy Clin. Immunol. pmid:9802361
Boguniewicz M et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. 1998 J. Allergy Clin. Immunol. pmid:9802373
Faure JD et al. An Arabidopsis immunophilin, AtFKBP12, binds to AtFIP37 (FKBP interacting protein) in an interaction that is disrupted by FK506. 1998 Plant J. pmid:9807817
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Hultsch T et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. 1998 Arch. Dermatol. Res. pmid:9808344
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496